Natco Pharma – Imminent Growth Cycle (?)

1. Yeah that impacted Q4FY22.
2. Based on the concall, only 25% of the Revlimid sales have been done by their partner and the revenue numbers are reflecting the same. The company is expecting that the majority of the 75% will be realized in Q1 and somewhat little in Q2.
3. They are hopeful to push the CTPR inventory between June to September during the Kharif season. They are confident of the product.

Based on the concall, I am expecting better days ahead for the company. Q1FY24 should be much stronger. Q2 should be better YoY.

Also I was able to sense that we can see an inorganic opportunity for Natco this year. Mr. Rajeev sounded quite optimistic about that.

Disclaimer: Invested, Transactions in last 30 days